Alpha Teknova, Inc. (TKNO) Fair Value 2026

TKNO · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Alpha Teknova, Inc. (TKNO) trades at $7.12. QOC: 5.8/10. Value Trap Risk: 26/100 (LOW). 0/13 models active.

Key Facts

Ticker
TKNO
Price
$7.12
Quality Score
5.8/10
Value Trap Risk
26/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give TKNO?

0 Intrinsic Value Models vs. Current Price ($7.12)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Alpha Teknova, Inc. (TKNO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Alpha Teknova, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About TKNO?

0 of 13 models are currently active for TKNO. See which stocks rank higher →

How Does TKNO Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, TKNO ranks #65 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Alpha Teknova, Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is TKNO a Value Trap?

CirclFi's Value Trap algorithm assigns TKNO a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Alpha Teknova, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Alpha Teknova, Inc. earns a quality score of 5.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TKNO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Alpha Teknova, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

BIOABioAge Labs, Inc.QOC 5.8RMTIRockwell Medical, Inc.QOC 5.8CBDYTarget Group Inc.QOC 5.8VRNOVerano Holdings Corp.QOC 5.7PRGOPerrigo Company plcQOC 5.9TLPHTalphera, Inc.QOC 5.7STEKStemtech CorporationQOC 4.5COLLCollegium Pharmaceutical, Inc.QOC 8.8TEVATeva Pharmaceutical Industries LimitedQOC 6.7UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: BIOA · RMTI · CBDY · VRNO · PRGO · TLPH · STEK · COLL · TEVA · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to TKNO?

7 companies across all industries closest to TKNO’s Quality of Company score of 5.8/10.

AIRGAirgain, Inc.QOC 5.8CCCCC4 Therapeutics, Inc.QOC 5.8PDYNPalladyne AI Corp.QOC 5.8CUECue Biopharma, Inc.QOC 5.8ACHAccendra Health, Inc.QOC 5.8AUGOAura Minerals Inc.QOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AIRG · CCCC · PDYN · CUE · ACH · AUGO · NVDA

Where Does TKNO Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

TKNO is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Alpha Teknova, Inc.’s Valuation?

What is Alpha Teknova, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Alpha Teknova, Inc. (TKNO). The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TKNO overvalued or undervalued right now?

At $7.12, 0 of 0 active models suggest TKNO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Alpha Teknova, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.8 mean for TKNO?

Alpha Teknova, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TKNO?

CirclFi analyzes TKNO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is TKNO a value trap in 2026?

Alpha Teknova, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Alpha Teknova, Inc. (TKNO) a Quality of Company score of 5.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/TKNO/ · Methodology
Primary sources for this TKNO valuation
  • Financial statements: Alpha Teknova, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001850902) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TKNO as of ; valuations recomputed .